Skip to main content
An official website of the United States government

Epstein Barr Virus Associated Lymphoma Consortium (EALC)

Hematoxylin and eosin (HE) staining of the Epstein-Barr virus (EBV).

The Epstein Barr Virus Associated-Lymphoma Consortium (EALC) is advancing the understanding of the role of Epstein Barr virus (EBV) infection on Non-Hodgkin Lymphoma and/or Hodgkin disease development with or without an underlying HIV/AIDS infection. 

The goal of the consortium is to increase knowledge about how EBV promotes Non-Hodgkin Lymphoma and/or Hodgkin disease initiation, progression, and resulting conditions, as well as to provide insights into mechanistic differences in the relationship between EBV infection and lymphoma development in individuals with HIV infection and those without an underlying HIV infection.  

EALC Funding Opportunity

PAR-21-348: The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)


New grants for the EALC were awarded in Fall 2022. 

Using single-cell sequencing and experimental models, Dr. Micah Luftig is characterizing and exploiting EBV-infected cell heterogeneity in non-Hodgkin lymphomas. 

Drs. Sumita Bhaduri-McIntosh and Michael McIntosh are investigating synthetic lethal therapeutic strategies for EBV-positive diffuse large B-cell lymphoma (DLBCL) in people living with HIV infection.  

Using preclinical models, Dr. Eric Johannsen is studying how an EBV protein interacts with the B cell receptor and maintains oncogenic antibody signaling in B cell lymphomas. 

Drs. Ethel Cesarman, Benjamin Gewurz, and Lisa Roth are examining biological interactions between EBV and B cells involved in viral latency, and how these mechanisms play a role in the development of lymphoma in individuals living with HIV.  

DCB Contact for EALC

For additional information about the EALC, please contact Dr. Betsy Read-Connole.

Funded Projects

Institution Principal Investigator(s) Center Title
Duke University  Micah A. Luftig Defining and exploiting EBV-infected cell heterogeneity in non-Hodgkin lymphomas
John Hopkins University Richard F. Ambinder, Rena Xian Investigating the EBV methylome in PLWH: Discovery and development of novel EBV diagnostics in plasma and saliva
Stanford University Olivia Martinez, Sheri M. Krams Epstein Barr virus driven mechanisms of post transplant lymphoproliferative disease
University of Florida  Sumita Bhaduri-McIntosh, Michael McIntosh Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
University of Wisconsin-Madison Eric C. Johannsen  Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
University of Wisconsin-Madison Shannon C. Kenney Roles of LMP1 and MYC in EBV-induced B-cell tumors
Washington University in St. Louis  Vikas R. Dharnidharka  Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)
Weill Cornell  Ethel Cesarman, Benjamin E. Gewurz, Lisa G. Roth

B cell determinants of EBV latency

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Epstein Barr Virus Associated Lymphoma Consortium (EALC) was originally published by the National Cancer Institute.”